• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

Recent Advances in the Study of Benzonitrile, 3-fluoro-4-(2-hydroxyethoxy)- (CAS: 917226-74-5)

The compound Benzonitrile, 3-fluoro-4-(2-hydroxyethoxy)- (CAS: 917226-74-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug development and therapeutic interventions. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential clinical applications.

Recent studies have highlighted the unique structural properties of Benzonitrile, 3-fluoro-4-(2-hydroxyethoxy)-, which make it a promising candidate for the development of novel kinase inhibitors. The presence of the fluoro and hydroxyethoxy functional groups in the benzonitrile scaffold has been shown to enhance its binding affinity to specific protein targets, particularly in the context of cancer therapy. Researchers have employed advanced computational modeling techniques to predict its interaction with key oncogenic kinases, such as EGFR and VEGFR, with promising in silico results.

In vitro and in vivo studies have further elucidated the compound's pharmacological profile. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that Benzonitrile, 3-fluoro-4-(2-hydroxyethoxy)- exhibits potent inhibitory activity against tumor cell proliferation, with IC50 values in the low micromolar range for several cancer cell lines. Additionally, the compound showed favorable pharmacokinetic properties, including good oral bioavailability and metabolic stability, which are critical for its development as a therapeutic agent.

Another significant area of research involves the compound's potential application in neurodegenerative diseases. Preliminary findings suggest that Benzonitrile, 3-fluoro-4-(2-hydroxyethoxy)- may modulate neuroinflammatory pathways, offering a novel approach to treating conditions such as Alzheimer's disease. However, further preclinical studies are required to validate these findings and assess the compound's safety and efficacy in relevant animal models.

The synthesis of Benzonitrile, 3-fluoro-4-(2-hydroxyethoxy)- has also been optimized in recent years, with researchers developing more efficient and scalable routes to produce the compound in high yields. Green chemistry approaches, such as the use of catalytic methods and environmentally friendly solvents, have been employed to minimize the environmental impact of its production. These advancements are crucial for ensuring the compound's availability for further research and potential commercialization.

In conclusion, Benzonitrile, 3-fluoro-4-(2-hydroxyethoxy)- (CAS: 917226-74-5) represents a promising candidate for various therapeutic applications, particularly in oncology and neurodegenerative diseases. Its unique structural features, combined with its favorable pharmacological properties, make it a valuable subject of ongoing research. Future studies should focus on elucidating its mechanism of action, optimizing its therapeutic efficacy, and evaluating its safety profile in clinical trials.

• 331-62-4(3-Fluoro-4-methoxybenzonitrile)
• 104197-15-1(3,5-Difluoro-4-methoxybenzonitrile)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)